Failure of Isoniazid Chemoprophylaxis during Infliximab Therapy by Fernández-Guerrero, Manuel L. et al.
LETTERS
1428  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 13, No. 9, September 2007
of isoniazid and the onset of PRCA, 
which can occur up to 6 months after 
start of treatment (3).
Clinicians treating patients with 
tuberculosis must be aware of this 
adverse reaction because failure to 
identify and discontinue isoniazid in 
patients with such a condition might 
lead to their illness and death. Given 
the ongoing worldwide HIV pandemic 
and the increase in tuberculosis it in-
duces, such adverse effects are more 
likely to be reported in the next few 
years.
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Failure of Isoniazid 
Chemoprophylaxis 
during Inﬂ  iximab 
Therapy
 To the Editor: A patient with an-
kylosing spondylitis was treated with 
inﬂ   iximab, a tumor necrosis factor 
(TNF) blocker that has been associated 
with reactivation of latent tuberculosis 
(TB). Because of reactivity in testing 
with puriﬁ  ed protein derivative, isoni-
azid chemoprophylaxis was started 2 
weeks before inﬂ  iximab therapy. Four 
months later, a cavitary lung infec-
tion developed in the patient, caused 
by isoniazid-resistant Mycobacterium 
kansasii.
To our knowledge, this is the ﬁ  rst 
documented case of failure of isonia-
zid prophylaxis due to the emergence 
of isoniazid-resistant mycobacteria in 
patients receiving inﬂ  iximab therapy. 
TNF blockers have contributed to the 
control of rheumatic diseases (1). Many 
of the damaging inﬂ  ammatory mecha-
nisms that they inhibit are important 
in maintaining TB in the latent phase. 
Consequently, drugs that target TNF 
functions have been associated with 
an increased risk of TB (2). For these 
reasons, prophylactic chemotherapy 
should be offered to patients with la-
tent TB (3). We show the failure of iso-
niazid chemoprophylaxis in a patient 
receiving inﬂ  iximab therapy in whom 
lung infection developed, caused by 
isoniazid-resistant M. kansasii.
A 39-year-old man with anky-
losing spondylitis was admitted to 
Jimenez Diaz Foundation hospital, 
Madrid, because of fever and lung in-
ﬁ  ltrates. He had been receiving anti-
inﬂ   ammatory drug therapy without 
amelioration of his symptoms. There-
fore, treatment with inﬂ  iximab  was 
considered. Fifteen years before, the 
patient’s father had had pulmonary 
TB caused by M. tuberculosis that was 
susceptible to ﬁ  rst-line  antitubercu-
lous drugs, and the patient was given 
chemoprophylaxis with isoniazid, 300 
mg/day, during a 9-month period. Be-
fore beginning inﬂ  iximab therapy, the 
patient was again given chemopro-
phylaxis with isoniazid, 300 mg/day, 
because a tuberculin test with 5 units 
of puriﬁ  ed protein derivative showed 
an induration of 18 mm at 72 hours. 
Results of chest radiographs were nor-
mal, and cultures for mycobacteria 
were negative. Results of HIV testing 
were also negative.
After 4 months of inﬂ  iximab 
therapy, fever, cough, and sputum pro-
duction developed. New radiographs 
showed bilateral upper lung ﬁ  eld in-
ﬁ   ltrates with cavitary lesions. Three 
acid-fast stains of sputum were posi-
tive, and treatment with rifampin, iso-
niazid, pyrazinamide, and ethambutol 
was started. 
A heavy growth of photochro-
mogenic mycobacteria was detected 
in 3 sputum cultures. The isolate was 
identiﬁ  ed as M. kansasii genotype 1 
by using common biochemical tests 
and PCR–restriction fragment length 
polymorphism analysis of the hsp65 
gene (4). Susceptibility tests showed 
resistance to isoniazid (>5 μg/mL), 
streptomycin, pyrazinamide, p-ami-
no-salicylic acid, and kanamycin but 
susceptibility to rifampin, ethambutol, 
and ﬂ  uoroquinolones. 
Treatment was continued with a 
combination of rifampin, levoﬂ  oxa-
cin, and ethambutol. Sputum cultures 
taken after 4, 6, and 9 months of an-
timicrobial drug therapy were nega-
tive. After 20 months of treatment, the 
patient was doing well with a partial 
resolution of lung inﬁ  ltrates, and new 
cultures were negative. 
Isoniazid chemoprophylaxis can 
effectively lessen the likelihood of ac-
tive TB in patients treated with TNF 
antagonists (5). However, at least 1 
failure of TB chemoprophylaxis in a 
severely immunocompromised patient 
treated with inﬂ  iximab and methotrex-
ate has been published (6). Our patient 
is unique because the mycobacterial 
lung infection seemed to emerge as 
a result of the lack of activity of iso-
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niazid chemoprophylaxis due to resis-
tance of the infecting organism.
Decreased susceptibility to iso-
niazid among M. kansasii isolates is 
common (7,8), and this microorgan-
ism is naturally resistant to pyrazin-
amide (9). This pattern of resistance is 
a serious obstacle for the use of these 
drugs in monotherapy or when com-
bined with rifampin in the prevention 
of lung disease caused by M. kansasii 
(10).
The source of the infection in this 
patient is unknown. In a large series 
of infectious diseases associated with 
inﬂ   iximab therapy, nontuberculous 
mycobacteria were isolated in 9% of 
the patients who had mycobacterial 
diseases (2). As in our patient, these 
infections developed shortly after ini-
tiation of treatment with inﬂ  iximab, 
which suggests that reactivation of a 
latent infection is the most probable 
origin of the disease. Although a mild-
ly positive tuberculin skin test result 
can be observed in patients infected 
with atypical mycobacteria, the strong 
reaction seen in this patient suggests 
a latent infection with M. tuberculosis 
(10). We could speculate on the possi-
bility of a double infection with M. tu-
berculosis (contracted through house-
hold contacts with his father) and M. 
kansasii through environmental expo-
sure. In this scenario, isoniazid che-
moprophylaxis could have prevented 
the former but not the latter.
In summary, failure of isoniazid 
chemoprophylaxis can be anticipated 
in patients who initiate treatment with 
inﬂ   iximab and who have latent in-
fections due to M. kansasii. Despite 
routine antituberculous chemopro-
phylaxis, patients receiving inﬂ  iximab 
therapy should be carefully evaluated 
for lung infection caused by atypical 
mycobacteria. 
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Jaime Esteban,* 
Carlos Acebes,* 
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Extensively 
Drug-Resistant 
Mycobacterium 
tuberculosis, India 
To the Editor: India is contrib-
uting nearly one third of the world’s 
tuberculosis (TB) cases and has the 
highest rate of new TB cases (1). 
Prevalence of multidrug-resistant TB 
(MDR TB) cases is on the rise in India, 
and proportions of new cases of MDR 
TB have been observed to vary from 
1.1% to 5.3% in most of the reported 
studies. The proportion of previously 
treated patients with MDR TB varied 
from 8% to 67% (2). Although these 
studies have been conducted in differ-
ent parts of India, they indicate an in-
creasing trend of MDR TB cases.
MDR TB cases threaten the ef-
fectiveness of chemotherapy for both 
treatment and control of TB and re-
quire the use of second-line drugs that 
are more expensive, toxic, and less 
effective than ﬁ  rst-line anti-TB drugs 
(3). The Green Light Committee es-
tablished by the Stop TB partners (4), 
which ensures the proper use of sec-
ond-line drugs to prevent increasing 
drug resistance in MDR TB cases in 
resource-limited countries, encoun-
tered resistance to these drugs. This 
led to the emergence of new termi-
nology in relation to drug-resistant 
TB, i.e., extensively drug-resistant 
TB (XDR TB). XDR TB is deﬁ  ned 
as TB caused by a Mycobacterium tu-
berculosis strain that is resistant to at 
least rifampin and isoniazid among the 
ﬁ  rst-line anti-TB drugs (MDR TB) in 
addition to resistance to any ﬂ  uoroqui-
nolones and at least 1 of 3 injectable 
second-line drugs (5). A recent report 
describes the current prevalence of 
XDR TB worldwide (6). Although In-
dia has high annual risk for TB cases 
and increasing prevalence of MDR TB 
cases, XDR TB has not yet been de-
scribed in India.
From December 2000 through 
December 2002, 68 MDR TB isolates 